Immune Pharmaceuticals to Announce Third Quarter 2015 Financial Results and Provide Corporate Update on November 12, 2015

Nov 5, 2015

NEW YORK, Nov. 5, 2015 /PRNewswire/ -- Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: IMNP) announced today it will release third quarter 2015 financial results and provide an update on company progress on Thursday November 12, 2015.

In connection with the release, Immune will host a conference call and live audio webcast at 11:00 am EDT on Thursday, November 12, 2015 to discuss results. Please dial/log-in approximately 5 minutes prior to the event to ensure a timely connection.

Conference Call Information:
Date: Thursday, November 12, 2015
Time: 11:00am EST
Domestic Dial-in Number (toll free US and Canada): 866-373-3402
International Dial-in Number: 201-689-7825
Live webcast: 

For those unable to participate in the conference call or live audio webcast, the recorded webcast will be available by visiting the Company's website at

About Immune Pharmaceuticals, Inc.

Immune applies a personalized approach to treating and developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune's lead product candidate, bertilimumab, is in clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Other indications considered for development include atopic dermatitis, Crohn's disease, severe asthma and NASH (inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology, topical nano-formulated Cyclosporine A for the treatment of psoriasis and atopic dermatitis. Immune's pipeline also includes NanomAbs®, antibody nano-conjugates, for the targeted delivery of chemotherapeutics. Immune's Pain pipeline including AmiKet™ are in a partnering process for further development and commercialization.

For more information, visit Immune's website at

SOURCE Immune Pharmaceuticals, Inc.

For further information: Immune Pharmaceuticals, Inc., Christine J. Petraglia, Director, Investor Relations, +1.646.440.9332,

print email rss